Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderate Psoriasis”

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT05728489
What this trial is testing

Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Who this might be right for
Psoriasis
Boehringer Ingelheim 64
Large-scale testing (Phase 3)Study completedNCT01358578
What this trial is testing

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Who this might be right for
Chronic Plaque Psoriasis
Novartis Pharmaceuticals 1,306
Post-approval studies (Phase 4)Study completedNCT02749799
What this trial is testing

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Primus Pharmaceuticals 45
Post-approval studies (Phase 4)Study completedNCT00663052
What this trial is testing

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis

Who this might be right for
Plaque PsoriasisPsoriasis
Pfizer 273
Large-scale testing (Phase 3)Study completedNCT03412747
What this trial is testing

Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Chronic Plaque PsoriasisModerate to Severe Plaque Psoriasis
UCB Biopharma SRL 478
Not applicableStudy completedNCT04053881
What this trial is testing

Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

Who this might be right for
Plaque Psoriasis
UCB Biopharma SRL 412
Not applicableActive Not RecruitingNCT04780516
What this trial is testing

Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care

Who this might be right for
Psoriasis
AbbVie 141
Not applicableStudy completedNCT02713295
What this trial is testing

Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece

Who this might be right for
Moderate to Severe Plaque Psoriasis
AbbVie 273
Large-scale testing (Phase 3)Study completedNCT03802344
What this trial is testing

This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream

Who this might be right for
Psoriasis Vulgaris
MC2 Therapeutics 498
Not applicableActive Not RecruitingNCT06104644
What this trial is testing

Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany

Who this might be right for
Plaque Psoriasis
Bristol-Myers Squibb 550
Post-approval studies (Phase 4)WithdrawnNCT04614298
What this trial is testing

Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Plaque Psoriasis
Kyowa Kirin Co., Ltd.
Not applicableUnknownNCT05326659
What this trial is testing

Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis

Who this might be right for
Psoriasis
Peking University People's Hospital 390
Testing effectiveness (Phase 2)Study completedNCT01595997
What this trial is testing

Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris

Who this might be right for
Mild-to-moderate Psoriasis Vulgaris
Delenex Therapeutics AG 20
Early research (Phase 1)Study completedNCT01937260
What this trial is testing

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

Who this might be right for
Psoriasis
Bausch Health Americas, Inc. 31
Testing effectiveness (Phase 2)Study completedNCT06109818
What this trial is testing

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Plaque Psoriasis
Beijing InnoCare Pharma Tech Co., Ltd. 129
Large-scale testing (Phase 3)Study completedNCT01555125
What this trial is testing

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

Who this might be right for
Moderate to Severe Plaque-type Psoriasis
Novartis Pharmaceuticals 177
Early research (Phase 1)Looking for participantsNCT07038720
What this trial is testing

UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Plaque PsoriasisHealthy Volunteer
Usynova Pharmaceuticals Ltd. 124
Large-scale testing (Phase 3)Study completedNCT03589885
What this trial is testing

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Novartis Pharmaceuticals 122
Large-scale testing (Phase 3)Looking for participantsNCT07672561
What this trial is testing

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Plaque Psoriasis
Zhejiang Wenda Pharma Technology LTD. 375
Large-scale testing (Phase 3)Study completedNCT02595970
What this trial is testing

Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis

Who this might be right for
Psoriasis
Novartis Pharmaceuticals 120
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation